2-Methyl-2-propyl-tetrahydro-furan | 92380-17-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: 2-Methyl-2-propyl-tetrahydro-furan
• 英文别名: 2-Methyl-2-propyloxolane
• CAS: 92380-17-1
• 化学式: C₈H₁₆O
• 分子量: 128.214
• InChiKey: GXFYZQLIPMQGHA-UHFFFAOYSA-N

物化性质

• 沸点：
  143.5-144.0 °C(Press: 750 Torr)
• 密度：
  0.8528 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Methyl-2-propyl-tetrahydro-furan 、 alkaline earth salt of/the/ methylsulfuric acid 生成 3-甲基已烷
  参考文献：
  名称：

  Schuikin et al., Doklady Akademii Nauk SSSR, 1959, vol. 127, p. 815

  摘要：

  DOI：
• 作为产物：
  描述：

  (Z)-4-methyl-hept-4-en-1-ol 在 Amberlyst H-15 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以98%的产率得到2-Methyl-2-propyl-tetrahydro-furan
  参考文献：
  名称：

  From intermolecular alcohol additions on a double bond to electrocyclizations of non-activated γ, δ-unsaturated alcohols: An easy synthesis of tetrahydrofurans

  摘要：

  Tetrahydrofurans have been synthesized in high yields through an electrocyclization reaction, by simple treatment of non activated gamma, delta- or beta, gamma-unsaturated alcohols with an acidic resin (Amberlyst H-15) in CH2Cl2 at room temperature. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)00081-6

文献信息

• Pyridine and Pyrazine derivative for the Treatment of CF
  申请人：BAETTIG Urs

  公开号：US20110230483A1

  公开（公告）日：2011-09-22

  The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供吡啶和吡嗪衍生物，可恢复或增强突变型和/或野生型CFTR的功能，用于治疗囊性纤维化、原发性纤毛运动障碍、慢性支气管炎、慢性阻塞性肺疾病、哮喘、呼吸道感染、肺癌、口干症和角膜结膜炎，或便秘（肠易激综合征、炎症性肠病、阿片类药物诱导）。还包括含有这些衍生物的药物组合物。
• Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
  申请人：Lead Discovery Center GmbH

  公开号：EP2634189A1

  公开（公告）日：2013-09-04

  The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.

  本发明涉及吡唑并[1,5-a][1,3,5]三嗪衍生物和/或其药用盐，这些衍生物作为药用活性剂的应用，特别是用于预防和/或治疗传染病，包括机会性感染病、免疫性疾病、自身免疫疾病、心血管疾病、细胞增殖性疾病、炎症、勃起功能障碍和中风，以及含有至少一种所述吡唑并[1,5-a][1,3,5]三嗪衍生物和/或其药用盐的药物组合物。此外，本发明涉及所述吡唑并[1,5-a][1,3,5]三嗪衍生物作为蛋白激酶抑制剂的应用。
• Pyridine and Pyrazine Derivative for the Treatment of CF
  申请人：BAETTIG Urs

  公开号：US20120277232A1

  公开（公告）日：2012-11-01

  The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了吡啶和吡嗪衍生物，用于恢复或增强突变和/或野生型CFTR的功能，以治疗囊性纤维化、原发性纤毛运动障碍、慢性支气管炎、慢性阻塞性肺疾病、哮喘、呼吸道感染、肺癌、口干症和角膜结膜炎，或便秘（IBS，IBD，阿片类药物引起）。还包括含有这些衍生物的制药组合物。
• COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2
  申请人：Elder Amy M.

  公开号：US20120208818A1

  公开（公告）日：2012-08-16

  The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R 1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.

  本发明提供了一般式I的化合物：或其药学上可接受的盐，其中X、n、Y和R1在本文中一般和子集中被定义。本发明的化合物是CCR2的抑制剂，因此可用于治疗各种炎症、过敏和自身免疫性疾病、紊乱或病况。
• Compounds for inhibiting NLRP3 and uses thereof
  申请人：Ventus Therapeutics U.S., Inc.

  公开号：US11319319B1

  公开（公告）日：2022-05-03

  The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):

  本公开涉及NLRP3抑制剂，用于治疗被该蛋白抑制的疾病和障碍，并具有公式（I）：